

FDA Public Meeting
Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment.

December 11, 2020
Virtual Meeting

Dear Speaker, Panelist, or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant G. Caleb Alexander

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

Dr. Alexander is past Chair of FDA's Peripheral and Central Nervous System Advisory Committee; has served as a paid advisor to IQVIA; is a co-founding Principal and equity holder in Monument Analytics, a health care consultancy whose clients include the life sciences industry as well as plaintiffs in opioid litigation; and is a member of OptumRx's National P&T Committee. This arrangement has been reviewed and approved by Johns Hopkins University in accordance with its conflict of interest policies.

Signature _____

 Alexander

Please email the form to Paul Tran (Paul.Tran@fda.hhs.gov) by November 20, 2020.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment.

December 11, 2020
Virtual Meeting

Dear Speaker, Panelist, or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant: Daren Anderson

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

none

Signature 

Please email the form to Paul Tran (Paul.Tran@fda.hhs.gov) by November 20, 2020.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment.

December 11, 2020
Virtual Meeting

Dear Speaker, Panelist, or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant William C. Becker, MD

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

no conflicts

Signature 

Please email the form to Paul Tran (Paul.Tran@fda.hhs.gov) by November 20, 2020.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment.

December 11, 2020
Virtual Meeting

Dear Speaker, Panelist, or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant ___Ronald M. Cervero, PhD_____

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

No Conflicts



Signature_____

Please email the form to Paul Tran (Paul.Tran@fda.hhs.gov) by November 20, 2020.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment.

December 11, 2020
Virtual Meeting

Dear Speaker, Panelist, or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant ___Kari Cruz, MPH_____

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

None



Signature_____

Please email the form to Paul Tran (Paul.Tran@fda.hhs.gov) by November 20, 2020.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment.

December 11, 2020
Virtual Meeting

Dear Speaker, Panelist, or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant James Floyd

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

Consulted for Shionogi Inc on topic unrelated to this meeting

Signature_ 

Please email the form to Paul Tran (Paul.Tran@fda.hhs.gov) by November 20, 2020.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment.

December 11, 2020
Virtual Meeting

Dear Speaker, Panelist, or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant Martin Garcia-Bunuel, MD

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

No Conflicts

Signature _____

Please email the form to Paul Tran (Paul.Tran@fda.hhs.gov) by November 20, 2020.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment.

December 11, 2020
Virtual Meeting


Dear Speaker, Panelist, or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant - Don Goldman

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

NOTHING TO DECLARE

Signature  November 7, 2020_____

Please email the form to Paul Tran (Paul.Tran@fda.hhs.gov) by November 20, 2020.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment.

December 11, 2020
Virtual Meeting

Dear Speaker, Panelist, or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant ____Lisa Howley, PhD____

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

No Conflicts

Signature  _____

Please email the form to Paul Tran (Paul.Tran@fda.hhs.gov) by November 20, 2020.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment.

December 11, 2020
Virtual Meeting

Dear Speaker, Panelist, or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant Joanna G. Katzman

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

NONE

Signature Joanna G. Katzman

Please email the form to Paul Tran (Paul.Tran@fda.hhs.gov) by November 20, 2020.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment.

December 11, 2020
Virtual Meeting

Dear Speaker, Panelist, or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant Marc Laroche

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

Research consulting funds paid to my institution for salary support by OptumLabs for research on treatment of opioid use disorder.

Signature 

Please email the form to Paul Tran (Paul.Tran@fda.hhs.gov) by November 20, 2020.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment.

December 11, 2020
Virtual Meeting

Dear Speaker, Panelist, or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant Jan L. Losby

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

No conflicts.

Signature Jan L. Losby

Please email the form to Paul Tran (Paul.Tran@fda.hhs.gov) by November 20, 2020.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment.

December 11, 2020
Virtual Meeting

Dear Speaker, Panelist, or Moderator:


Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant ____Graham McMahon MD MMSc____

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

No conflicts

Signature _____



Please email the form to Paul Tran (Paul.Tran@fda.hhs.gov) by November 20, 2020.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment.

December 11, 2020
Virtual Meeting

Dear Speaker, Panelist, or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant _____ Elaine H. Morrato, DrPH MPH

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

No conflicts.

Signature Elaine H. Morrato

Please email the form to Paul Tran (Paul.Tran@fda.hhs.gov) by November 20, 2020.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment.

December 11, 2020
Virtual Meeting


Dear Speaker, Panelist, or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant Jesse Roach

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

No Conflicts

Signature 

Please email the form to Paul Tran (Paul.Tran@fda.hhs.gov) by November 20, 2020.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment.

December 11, 2020
Virtual Meeting

Dear Speaker, Panelist, or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant ___Friedhelm Sandbrink MD___

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

No conflicts.

Signature Friedhelm Sandbrink Nov 17, 2020

Please email the form to Paul Tran (Paul.Tran@fda.hhs.gov) by November 20, 2020.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment.

December 11, 2020
Virtual Meeting


Dear Speaker, Panelist, or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant DAVID THOMAS

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

NO CONFLICTS

Signature 

Please email the form to Paul Tran (Paul.Tran@fda.hhs.gov) by November 20, 2020.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment.

December 11, 2020
Virtual Meeting


Dear Speaker, Panelist, or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant Alexander M. Walker

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

Prepared white paper for REMS Program Companies entitled "Options for Evaluating the Impact of REMS-Compliant Continuing Education on Opioid Prescribing Practices, Patient Management and Patient Outcomes" on July 11, 2019, with an addendum. No other work on Continuing Education Programs. Participated in OPC PMS 3033-2 and 3033-7. Participated in Purdue PMS 3051-4 and additionally advised Purdue on PMS 3051-1, -2 and -3.

Signature 

Please email the form to Paul Tran (Paul.Tran@fda.hhs.gov) by November 20, 2020.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment.

December 11, 2020
Virtual Meeting

Dear Speaker, Panelist, or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant ____ Julie L. White _____

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

None

Signature _____  _____

Please email the form to Paul Tran (Paul.Tran@fda.hhs.gov) by November 20, 2020.

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable.

FDA Public Meeting
Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment.

December 11, 2020
Virtual Meeting

Dear Speaker, Panelist, or Moderator:

Please complete this form regarding disclosure of financial or other beneficial interests in matters that will be discussed at the assessment of the Evaluating the Effect of the Opioid Analgesics Risk Evaluation and Mitigation Strategy Education Program on Prescribing Behaviors and Patient Outcomes--Exploring the Path Forward for Assessment. **This information will be posted publicly along with the transcript, slides and other material from the workshop in a fashion similar to disclosure statements in a scientific journal.**

Name of Meeting Participant Almut Winterstein

Please list any financial arrangement or affiliation or other beneficial interest in the past three years with any products, or firms relevant to the discussions. Examples of potential conflicts of interest include financial investments or other beneficial interests in organizations involved in the development of relevant products, employee of a pharmaceutical company, consultancy for a pharmaceutical company, serving on a speakers bureau or receiving funding, grants or contracts from a pharmaceutical company. If you have no conflicts of interest to report, please state "no conflicts", sign and return the form.

I have research funding from Merck Sharp Dohme for a study on respiratory syncytial virus infections in children. I have no industry funding related to analgesics.



Signature _____ !

Please email the form to Paul Tran (Paul.Tran@fda.hhs.gov) by November 20, 2020. !

Note to Speakers: We also request that you include this information as the second slide of your presentations, if applicable. !